Afabicin

DB15268InvestigationalSmall molecule

Afabicin is under investigation in clinical trial NCT03723551 (Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus).

Mechanism: Pharmacologically active on Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI
Curator reviewed
Formula / weight: C₂₃H₂₄N₃O₇P · 485.433 g/mol (avg)

Resolves to

Compound

UNIIDMM8663H2RCAS1518800-35-5

Structure

InChIKeyHFYMDQMXVPJNTH-VQHVLOKHSA-NSMILESCN(CC1=C(C)C2=CC=CC=C2O1)C(=O)\C=C\C1=CN=C2N(COP(O)(O)=O)C(=O)CCC2=C1

Targets

Q6GI75fabI

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Afabicin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account